Evaxion A/S (NASDAQ:EVAX) Announces Quarterly Earnings Results

Evaxion A/S (NASDAQ:EVAX) released its quarterly earnings data on Thursday. The company reported $0.73 earnings per share for the quarter, Zacks reports.

Evaxion A/S Stock Down 7.6%

Shares of NASDAQ EVAX traded down $0.47 during mid-day trading on Friday, hitting $5.79. 98,790 shares of the stock traded hands, compared to its average volume of 1,190,250. The company has a market cap of $36.55 million, a price-to-earnings ratio of -4.39 and a beta of 0.28. The stock has a fifty day moving average price of $4.85 and a 200-day moving average price of $3.25. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $13.15. The company has a debt-to-equity ratio of 1.73, a quick ratio of 3.42 and a current ratio of 3.42.

Analyst Ratings Changes

A number of research firms recently commented on EVAX. Edward Jones started coverage on shares of Evaxion A/S in a report on Thursday, October 30th. They set a “buy” rating and a $10.00 price target for the company. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. Lake Street Capital increased their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, October 20th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.